Vaxart Past Earnings Performance
Past criteria checks 0/6
Vaxart's earnings have been declining at an average annual rate of -45.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 63.7% per year.
Key information
-45.1%
Earnings growth rate
91.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -63.7% |
| Return on equity | -47.8% |
| Net Margin | -16,892.6% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vaxart makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -80 | 23 | 0 |
| 31 Dec 21 | 1 | -70 | 22 | 0 |
| 30 Sep 21 | 1 | -64 | 21 | 0 |
| 30 Jun 21 | 1 | -54 | 20 | 0 |
| 31 Mar 21 | 2 | -47 | 19 | 0 |
| 31 Dec 20 | 4 | -32 | 15 | 0 |
| 30 Sep 20 | 8 | -25 | 11 | 0 |
| 30 Jun 20 | 8 | -22 | 9 | 0 |
| 31 Mar 20 | 7 | -19 | 6 | 0 |
| 31 Dec 19 | 10 | -19 | 6 | 0 |
| 30 Sep 19 | 8 | -17 | 6 | 0 |
| 30 Jun 19 | 8 | -18 | 6 | 0 |
| 31 Mar 19 | 8 | -22 | 7 | 0 |
| 31 Dec 18 | 4 | -18 | 7 | 0 |
| 30 Sep 18 | 3 | -15 | 6 | 0 |
| 30 Jun 18 | 4 | -12 | 5 | 0 |
| 31 Mar 18 | 5 | -7 | 3 | 0 |
| 31 Dec 17 | 6 | -12 | 3 | 0 |
| 30 Sep 17 | 9 | -16 | 3 | 0 |
| 31 Dec 16 | 8 | -19 | 3 | 0 |
| 31 Dec 15 | 0 | -22 | 3 | 0 |
Quality Earnings: NB11 is currently unprofitable.
Growing Profit Margin: NB11 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NB11 is unprofitable, and losses have increased over the past 5 years at a rate of 45.1% per year.
Accelerating Growth: Unable to compare NB11's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NB11 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: NB11 has a negative Return on Equity (-47.82%), as it is currently unprofitable.